Yes, this prescription is appropriate for unspecified multiple sclerosis
The prescribed regimen of Rebif (interferon beta-1a) 44 mcg subcutaneously three times weekly on Monday, Wednesday, and Friday is FDA-approved and appropriate for treating relapsing forms of multiple sclerosis, which includes the diagnosis of unspecified MS (G35.D). 111
FDA-Approved Indication and Dosing
Rebif is specifically indicated for treatment of relapsing forms of MS, including:
- Clinically isolated syndrome
- Relapsing-remitting disease
- Active secondary progressive disease
The FDA label explicitly states the recommended dose is either 22 mcg or 44 mcg injected subcutaneously three times per week, administered on the same three days (e.g., Monday, Wednesday, Friday) at least 48 hours apart 111. The prescription matches this exactly.
Critical Prescribing Considerations
However, there is one important caveat: The FDA label recommends patients should be started at 20% of the prescribed dose and titrated up over a 4-week period to minimize adverse events 11. For the 44 mcg target dose, the titration schedule is:
- Weeks 1-2: 8.8 mcg three times weekly
- Weeks 3-4: 22 mcg three times weekly
- Week 5 onward: 44 mcg three times weekly (full dose)
The prescription as written ("inject 1 syringe...one time a day every Mon, Wed, Fri") appears to start at full dose without titration. This should be corrected to include the 4-week titration period unless the patient is already established on this medication. Dose titration significantly reduces flu-like symptoms and adverse events 2.
Supporting Evidence
Clinical trials demonstrate that interferon beta-1a 44 mcg three times weekly reduces relapse rates, delays disability progression, and decreases MRI lesion activity in relapsing MS 345. The three-times-weekly dosing schedule has been validated over 25 years of clinical use with established long-term safety data 67.
Additional Safety Monitoring Required
Patients on Rebif require monitoring for:
- Hepatotoxicity: Check liver function tests regularly; dose reduction or discontinuation may be needed if elevated 1
- Hematologic abnormalities: Monitor complete blood counts for cytopenias 1
- Injection site reactions: Rotate injection sites to minimize risk of necrosis or localized infection 1
- Depression and suicidal ideation: Screen for mood changes 1
Premedication with analgesics/antipyretics on injection days is recommended to manage flu-like symptoms 1.
Common Pitfall to Avoid
The prescription states "one time a day" which is technically incorrect terminology—it should specify "three times per week" to avoid confusion. While the days (Mon, Wed, Fri) are correctly specified, clarifying this is a thrice-weekly (not daily) regimen prevents potential dosing errors.